Involvement of endogenously synthesized interleukin (IL)-18 in the protective effects of IL-12 against pulmonary infection with Cryptococcus neoformans in mice
K. Kawakami et al., Involvement of endogenously synthesized interleukin (IL)-18 in the protective effects of IL-12 against pulmonary infection with Cryptococcus neoformans in mice, FEMS IM MED, 27(3), 2000, pp. 191-200
We previously demonstrated that interleukin (IL)-12 protected mice against
fatal pulmonary infection with a highly virulent strain of Cryptococcus neo
formans, which correlated well with the production of interferon (IFN)-gamm
a as well as IL-18 in the primary infected site. In the present study, we e
xamined the role of endogenously synthesized IL-18 in IL-12-induced host re
sistance to this pathogen. There was little or no production of IFN-gamma a
nd IL-18 both at mRNA and protein levels in lungs of mice infected with C,
neoformans, while treatment with IL-IZ induced a marked production of these
cytokines. Caspase-1 mRNA was expressed in infected mice even without IL-1
2 treatment. Administration of neutralizing anti-IFN-gamma monoclonal antib
ody (mAb) clearly inhibited production of IFN-gamma and TL-18 induced by IL
-12, while control IgG did not show such an effect. However, administration
of IFN-gamma did not induce the production of both cytokines in infected m
ice, although tumor necrosis Factor (TNF)-alpha and IFN-gamma-inducible pro
tein (IP)10 were synthesized by the same treatment. Finally, neutralizing a
nti-IL-Is antibody (Ab) significantly interfered with the production of IFN
-gamma and elimination of the microorganism from the lung induced by IL-12
treatment. Furthermore, both IFN-gamma synthesis and host protection caused
by IL-12 were profoundly diminished in IL-18 gene-disrupted mice. Consider
ed collectively, our results indicated that host protection against C. neof
ormans induced by IL-12 involved endogenously synthesized IL-18 and that th
e production of IL-18 was mediated at least in part by endogenous IFN-gamma
. (C) 2000 Elsevier Science B.V. All nights reserved.